A few months after Entereg missed its endpoint in a Phase III European trial for post-operative ileus, the drug showed some promising benefits in a Phase II trial for opioid-induced bowel dysfunction, which Adolor Corp. reported Tuesday. (BioWorld Today)
Cell Therapeutics Inc. lost almost half of its value Monday, following news that Xyotax missed the primary endpoint in its Stellar 3 pivotal trial in non-small-cell lung cancer patients. (BioWorld Today)
Two serious adverse events - one ending in death - was enough for Biogen Idec Inc. and Elan Corp. plc to suspend marketing of their multiple sclerosis drug, Tysabri, just three months after FDA approval. (BioWorld International)
Two serious adverse events - one ending in death - was enough for Biogen Idec Inc. and Elan Corp. plc to suspend marketing of their multiple sclerosis drug, Tysabri, just three months after FDA approval. (BioWorld Today)
Alteon Inc. voluntarily suspended enrollment in its ongoing Phase II trials of alagebrium after preclinical data indicated high doses of the therapy could be associated with liver cell alterations and tumors. (BioWorld Today)
Although it had plenty of money in the bank, Idun Pharmaceuticals Inc. made a strategic decision to become part of a big pharmaceutical company that will help advance its lead liver disease product. (BioWorld Today)
With an FDA nod for its vaccinia immune globulin, DVC LLC will provide the U.S. military with a product addressing the serious side effects of the smallpox vaccine. (BioWorld Today)
